Tilray Canada and Sandoz’s Canadian arm plan to jointly operate in jurisdictions where cannabis is or will be approved for medical purposes.
Shares of Tilray surged in Tuesday afternoon trading after the medical cannabis company announced that one of its subsidiaries struck a collaboration agreement with pharmaceutical company Sandoz AG.
Under the deal, Tilray Canada Ltd. and Sandoz’s Canadian arm plan to jointly operate in jurisdictions where cannabis is or will be approved for medical purposes. The agreement also allows the companies to potentially collaborate in such areas as co-branding certain non-smokable/non-combustible products and developing new medical cannabis products.
Tilray has products available in 12 countries and operations in Australia, New Zealand, Canada, Germany, Latin America and Portugal. It is a subsidiary of Seattle-based Privateer Holdings.
Tilray Inc.’s stock jumped more than 15 percent to $76.05 in afternoon trading.
Most Read Business Stories
- Airbus's A380 failure ripples through its rivalry with Boeing in complex ways
- Property taxes dropping in half of King County cities after years of big increases
- Amazon: Canceled New York jobs likely to go elsewhere; company will 'continue to evaluate' growth in Seattle
- As businesses dig out of the snow, some also face digging out of the red
- Alaska Air to appeal $78 million judgment over pay for Virgin America flight attendants
Sandoz is a unit of Swiss pharmaceutical company Novartis AG. Its shares dipped 25 cents to $85.51 in afternoon trading.